Damora Therapeutics
GLTO | NASDAQ
$21.58
-$0.75 (-3.36%)
At close: Jun 4, 2026, 12:02 PM ET
-3.36%
(1D)Rating
Key Statistics
Market Data
Market Cap $34.47M
1D Range
21.58 23.54
52W Range
2.01 38.33
Valuation (TTM)
PE -0.17
PB 0.07
EV/EBITDA 1.90
Valuation (NTM)
Forward PE N/A
Forward PEG -0.05
Price Target $35.25
Cash Flow
FCF Yield -129.1%
SBC Adj. FCF Yield -157.9%
SBC Impact -22.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -93.7% |
-17.4%
FCF 3Y | 5Y -24.9% |
9.6%
Returns
ROA -48.4%
ROE -82.6%
ROIC -52.4%
Financial Health
Net Cash
$540.52M
Current Ratio 19.73
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a inves...
Sector Healthcare
Industry Medical - Pharmaceuticals
Employees 7
IPO Date Oct 28, 2020
Website damoratx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$42.50
Upside
+96.94%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove GLTO